Navigation Links
Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma

eb site at www.accentia.net.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune(TM) SinuNase(TM), BiovaxID(TM), AutovaxID(TM), CRSFungal Profile(TM) and any other statements relating to products, product candidates, product development programs the FDA or clinical study process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.

Contact

Biovest International, Inc., New York, NY
Steven Arikian, MD
Chairman and Chief Executive Officer
212-686-4100 ext 8640





Page: 1 2 3 4 5

Related medicine technology :

1. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
2. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
3. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
4. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
5. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
6. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
7. Research Indicates Gerons Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Othera Pharmaceuticals Announces Upcoming Presentation Based Upon Expanded Understanding of Lead Compound Mechanism of Action
Post Your Comments:
(Date:12/24/2014)... , Dec. 23, 2014 Echo ... medical device company focused on skin permeation, continuous ... Scott W. Hollander has been appointed ... Hollander has more than 20 years of experience ... industries, and most recently served as Vice President, ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced its victory ... manufacturer BMC Medical Co., Ltd. The International ... infringe ResMed,s patents, and entered an order prohibiting BMC from ... United States : , iVolve nasal mask ... pillows mask , iVolve full face mask ...
(Date:12/24/2014)... LEXINGTON, Mass. , Dec. 23, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing therapeutic products ... European Medicines Agency (EMA) of the Marketing Authorization ... The EMA recently granted the company,s request for ... the EMA,s regulatory review time.   ...
Breaking Medicine Technology:Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3
... 2011 "Blueprint to Quit" is a comprehensive ... interested in quitting, available exclusively at Walmart. Through ... support resources on QuitNet.com – including trained experts ... tools – and nicotine replacement therapy (NRT) to ...
... ULURU Inc. (NYSE AMEX: ULU ) today announced its ... For the third quarter of 2011, the Company reported a net loss ... of $1.2 million, or $0.22 per share, for the same period last ... a net loss of $3.2 million, or $0.55 per share, compared with ...
Cached Medicine Technology:New "Blueprint to Quit" Comprehensive Smoking Cessation Program Available for Smokers 2New "Blueprint to Quit" Comprehensive Smoking Cessation Program Available for Smokers 3New "Blueprint to Quit" Comprehensive Smoking Cessation Program Available for Smokers 4ULURU Inc. Reports Third Quarter 2011 Financial Results 2ULURU Inc. Reports Third Quarter 2011 Financial Results 3ULURU Inc. Reports Third Quarter 2011 Financial Results 4ULURU Inc. Reports Third Quarter 2011 Financial Results 5ULURU Inc. Reports Third Quarter 2011 Financial Results 6
(Date:12/26/2014)... Aliso Viejo, California (PRWEB) December 26, 2014 ... have announced the TransPack Volume 5 Plugin for Final Cut ... to manipulate a hard light tool to pull off an ... Studios. “When users get their hands on TransPack Volume 5, ... TransPack Volume 5 is a set of over 50 Final ...
(Date:12/26/2014)... DW-InductionHeating.com (DaWei Induction Heating Co.) is a ... producing and marketing of a series of induction heating ... new series of induction brazing equipments . , ... induction brazing refers to the joining of two ... heat. The manager says that there are fundamental differences ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Induction Brazing Equipment Series From DaWei Induction Heating Co., A Reliable Supplier Of Induction Heating Equipment 2Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... face transplant patient, Isabelle Dinoire, is jeopardizing her chances of ... since she is using her new lips to smoke, //there ... healing, which could prove to be a complication. ... the French team of doctors in performing the first ever ...
... science, doctors under the leadership of Dr Hasan Alam, a ... surgery on patients while they// are in a state between ... their bodies while the surgery is being performed and then ... ,The return of blood would be done after ...
... of North Carolina (UNC) at Chapel Hill have revealed that ... affected by cystic fibrosis (CF). Hypertonic saline// is a ... ,The researchers arrived at this conclusion after testing 24 ... that inhaling the salt solution improved the health of the ...
... was conducted to assess the health of the both wine ... among the wine drinkers were low when compared to those ... by both the population. // ,Morten Gr?nb?k, M.D., ... Health conducted the research in Denmark. The researchers started ...
... Member of African Subcommittee, House Committee on International Relations ... house AIDS testing and counseling as done in Uganda. ... very effective in early diagnosis of HIV and also ... positive person due to ignorance about the disease. ...
... once a day for treating AIDS is sought to be developed ... The regimen of three drugs will be contained in the pill, ... 2006. //As many as 40 million people across the world are ... the numbers. The US is reported to have 1 million AIDS ...
Cached Medicine News:Health News:Wine Drinkers Good Health, Attributed To Their Lifestyle 2
...
...
...
... a cutting-edge ECG management system ... and convenient, web-based access to ... information technology (IT) benefits, resulting ... and improved patient care. ...
Medicine Products: